Functional Service Provider (FSP) Medical Writing

Dedicated, sponsor-aligned medical writers embedded within your organization to provide scalable expertise across the development lifecycle.  

Embedded Medical Writing

When development portfolios expand, organizational structures shift, or internal teams reach capacity; medical writing can quickly become a bottleneck to regulatory progress.

ProPharma's FSP Medical Writing model provides dedicated, sponsor-aligned writers who integrate seamlessly into your organization, delivering continuity, scalability, and deep therapeutic expertise without increasing permanent headcount.

FSP models don't just add capacity, they create meaningful "organizational leverage". By shifting the operational management to the FSP partner, organizations significantly reduce administrative burden and unlock strategic capacity. Internal teams are no longer absorbed by managing the day-to-day execution and can instead focus on high-impact priorities such as advancing scientific strategy, shaping regulatory positions, and driving portfolio-level decisions.

Rather than outsourcing individual documents, this model delivers long-term capability: a stable team that operates within your processes, systems, and governance framework.

For project‑based deliverables, explore our Global Medical Writing & Transparency services.

Why Organizations Turn to FSP Medical Writing

Many sponsors adopt an FSP model during periods of transition, growth, or sustained volume pressure. Common drivers include:

  • Acquisition or in-licensing of new compounds that strain existing resources
  • Organizational restructuring that shifts ownership of programs or therapeutic areas
  • Lack of specialized expertise required for complex or niche document types
  • Headcount or budget constraints that prevent permanent hiring
  • Sudden increases in document volume during key development phases
  • Temporary staffing gaps due to extended leave or internal redeployment
  • Learn more about our broader Functional Service Provider capabilities.

Pharma-New-Blogs-8

A Seamless Extension of Your Internal Team

Dedicated FSP writers function as an extension of your internal medical writing organization. We use your SOPs, templates, quality expectations, systems, and governance structure, participating in established communication and review processes. This embedded approach reduces onboarding time, preserves institutional knowledge, and enables consistent output across programs.

Support Across the Development Continuum

FSP Medical Writing teams can support document development across all stages of the drug development lifecycle:

computer-system-validation

Non-Clinical Development

  • Study reports and summaries
  • Investigator's Brochure (Tox, ADME, CMC, etc.)
  • Pharmacology and toxicology documentation
Submissions

Clinical & Regulatory Development

  • Protocols, protocol amendments, and Informed Consent Forms (ICFs)
  • Clinical study reports (CSRs)
  • IND/NDA/BLA submission documentation
  • Safety narratives and summaries
  • Briefing packages and health authority responses
full-service-clinical-trials

Post-Market Safety & Lifecycle Management

  • Periodic safety reports
  • Benefit-risk assessments
  • Lifecycle maintenance documentation
global-literature-review

Publications & Scientific Communication

  • Manuscripts and abstracts
  • Conference materials and presentations
  • Literature reviews and scientific summaries

Peer-Reviewed Journals & Scientific Support

Publishing in peer-reviewed journals is essential for scientific credibility, regulatory engagement, and clinical adoption. FSP teams provide dedicated support across the publication lifecycle: Manuscripts and abstracts

  • Manuscript development for peer-reviewed journals
  • Abstract preparation and conference submissions
  • Journal selection guidance
  • Literature synthesis and evidence framing
  • Author coordination and review management
  • Response-to-reviewer preparation and revisions
  • Compliance with publication guidelines (e.g., ICMJE, GPP)
  • Alignment with Medical Affairs publication strategies
Hands typing on laptop
Woman pointing her coworkers to something on a laptop

Tailored Support Across Biopharma and MedTech

ProPharma supports biotech, pharmaceutical, and medical device/diagnostics organizations navigating diverse regulatory pathways and evidence requirements. Teams are matched to program complexity, therapeutic area, and modality to ensure relevant expertise and regulatory alignment.

Flexible, Scalable Team Structures

FSP Medical Writing solutions are designed to scale with evolving program needs:
  • Single dedicated writers for focused support
  • Multi-writer teams aligned to large portfolios
  • Therapeutic-area specialists
  • Regional expertise for global development
  • Rapid scale-up or scale-down as priorities shift

When an FSP Model is the Right Choice

This model is particularly effective when organizations require ongoing support across multiple programs, predictable demand over extended timelines, integration with internal teams, or scalability without hiring delays.

Shifting operational responsibilities can help reduce administrative and operational burden, allowing internal teams to reclaim time and focus. The result is a more agile, strategically aligned writing function that supports faster, more confident organizational progress.

AdobeStock_714056211

Build the Team That Moves Your Pipeline Forward

Our FSP Medical Writing solutions provide the stability, expertise, and flexibility needed to sustain development momentum, even as priorities evolve. Contact our team to discuss how an embedded medical writing model can support your organization’s goals.

News & Insights

Navigating Medical Inquiries Across Europe: Why Multilingual Support Matters for MAHs

April 13, 2026

Navigating Medical Inquiries Across Europe: Why Multilingual Support Matters for...

Discover why multilingual support and regional expertise are crucial for Marketing Authorization Holders (MAHs) to deliver consistent, compliant Medical Information across Europe's diverse landscape.

From Reactive to Proactive: The New MAH Compliance Standard

April 9, 2026

From Reactive to Proactive: The New MAH Compliance Standard

Marketing Authorization Holders must adopt proactive compliance strategies to navigate evolving regulatory landscapes and protect product quality and patient safety.

The IND is More Just an FDA Submission: It’s a Regulatory Positioning Strategy

April 6, 2026

The IND is More Just an FDA Submission: It’s a Regulatory Positioning Strategy

Learn why the IND is no longer just a filing but a critical regulatory positioning strategy. Discover how to align with FDA early and reduce development risk.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Case Study How a Novel Real World Evidence Strategy Helped Bring a Class III Device to Market - ProPharma

March 23, 2026

Real World Evidence for Class III Devices: A Smarter Path to PMA

Struggling to generate clinical evidence for Class III devices without costly, multi-year trials? Discover how ProPharma helped an orthopedic device company leverage existing registry data to support...

Flyers CMO Compass & Supply Chain Management - ProPharma

March 16, 2026

CMO Compass & Supply Chain Management

ProPharma provides comprehensive supply chain management and consulting services to support the efficient delivery of clinical trial materials throughout the product lifecycle. Using its CMO Compass®...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

March 12, 2026

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

Uncover the intricacies of Pharmacovigilance System Master File (PSMF) management and explore proven strategies to ensure inspection readiness, effective MAH oversight, and regulatory compliance...

News & Insights

Navigating Medical Inquiries Across Europe: Why Multilingual Support Matters for MAHs

April 13, 2026

Navigating Medical Inquiries Across Europe: Why Multilingual Support Matters for...

Discover why multilingual support and regional expertise are crucial for Marketing Authorization Holders (MAHs) to deliver consistent, compliant Medical Information across Europe's diverse landscape.

From Reactive to Proactive: The New MAH Compliance Standard

April 9, 2026

From Reactive to Proactive: The New MAH Compliance Standard

Marketing Authorization Holders must adopt proactive compliance strategies to navigate evolving regulatory landscapes and protect product quality and patient safety.

The IND is More Just an FDA Submission: It’s a Regulatory Positioning Strategy

April 6, 2026

The IND is More Just an FDA Submission: It’s a Regulatory Positioning Strategy

Learn why the IND is no longer just a filing but a critical regulatory positioning strategy. Discover how to align with FDA early and reduce development risk.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Case Study How a Novel Real World Evidence Strategy Helped Bring a Class III Device to Market - ProPharma

March 23, 2026

Real World Evidence for Class III Devices: A Smarter Path to PMA

Struggling to generate clinical evidence for Class III devices without costly, multi-year trials? Discover how ProPharma helped an orthopedic device company leverage existing registry data to support...

Flyers CMO Compass & Supply Chain Management - ProPharma

March 16, 2026

CMO Compass & Supply Chain Management

ProPharma provides comprehensive supply chain management and consulting services to support the efficient delivery of clinical trial materials throughout the product lifecycle. Using its CMO Compass®...

Previous Resource Arrow Next Resource Arrow
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

March 12, 2026

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

Uncover the intricacies of Pharmacovigilance System Master File (PSMF) management and explore proven strategies to ensure inspection readiness, effective MAH oversight, and regulatory compliance...

Previous Webinar Arrow Next Webinar Arrow